<DOC>
	<DOCNO>NCT01689129</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy new formulation insulin glargine Lantus term change HbA1c baseline endpoint ( schedule month 6 [ week 26 ] ) japanese patient type 1 diabetes mellitus Secondary Objectives : To compare new formulation insulin glargine Lantus term change fast plasma glucose ( FPG ) , preinjection plasma glucose , 8-point self-measured plasma glucose ( SMPG ) profile . To compare new formulation insulin glargine Lantus term occurrence hypoglycemia</brief_summary>
	<brief_title>Comparison New Formulation Insulin Glargine With Lantus® Japanese Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The duration study consist : - Up 2-week screening period ; - 6-month open-label comparative efficacy safety treatment period ; - 6-month open-label comparative safety extension period ; - 4-week post-treatment safety follow-up period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients type 1 diabetes mellitus Exclusion criterion : Age &lt; 18 year screen visit ; HbA1c &lt; 7.0 % &gt; 10.0 % ( national glycohemoglobin standardization program [ NGSP ] value ) screen visit ; Patients le 1 year screen visit basal plus mealtime insulin ; Patients stable insulin dose ( ±20 % total basal insulin dose ) last 30 day prior screen visit ; Patients use premix insulin , human regular insulin mealtime insulin and/or glucoselowering drug basal insulin mealtime rapidinsulin analogue last 3 month screen visit ; Use insulin pump last 6 month screen visit and/or plan switch insulin pump next 12 month ; Severe hypoglycemia result coma/seizures , and/or hospitalization diabetic ketoacidosis last 6 month screen visit ; Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( eq , laser , surgical treatment injectable drug ) study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>